Abstract
Analysis of The Cancer Genome Atlas data revealed that alternative splicing (AS) events could serve as prognostic biomarkers in various cancer types. This study examined lung adenocarcinoma (LUAD) tissues for AS and assessed AS events as potential indicators of prognosis in our cohort. RNA sequencing and bioinformatics analysis were performed. We used SUPPA2 to analyze the AS profiles. Using univariate Cox regression analysis, overall survival (OS)-related AS events were identified. Genes relating to the OS-related AS events were imported into Cytoscape, and the CytoHubba application was run. OS-related splicing factors (SFs) were explored using the log-rank test. The relationship between the percent spliced-in value of the OS-related AS events and SF expression was identified by Spearman correlation analysis. We found 1957 OS-related AS events in 1151 genes, and most were protective factors. Alternative first exon splicing was the most frequent type of splicing event. The hub genes in the gene network of the OS-related AS events were FBXW11, FBXL5, KCTD7, UBB and CDC27. The area under the curve of the MIX prediction model was 0.847 for 5-year survival based on seven OS-related AS events. Overexpression of SFs CELF2 and SRSF5 was associated with better OS. We constructed a correlation network between SFs and OS-related AS events. In conclusion, we identified prognostic predictors using AS events that stratified LUAD patients into high- and low-risk groups. The discovery of the splicing networks in this study provides an insight into the underlying mechanisms.
Highlights
Lung cancer is one of the most common malignant neoplasms worldwide with 2.1 million new cases and 1.8 million deaths in 2018 [1]
We applied univariate Cox regression analysis of overall survival (OS) to evaluate the prognostic impact of each alternative splicing (AS) event and to explore the prognostic value of the AS events in lung adenocarcinoma (LUAD) patients
We identified AS events and regulatory splicing factors (SFs) through an analysis of our LUAD cohort to explore the clinical significance of differential RNA splicing patterns
Summary
Lung cancer is one of the most common malignant neoplasms worldwide with 2.1 million new cases and 1.8 million deaths in 2018 [1]. Genetic susceptibility is a lung cancer risk factor [2]. Numerous lung cancer genomic studies have shown hot gene mutations, such as in the EGFR, TP53, KRAS and BRAF genes, and these driver genes have shown ethnic differences [5,6]. Much effort has been spent developing new molecular targeted therapies and immunotherapy agents, the 5-year survival rate of patients with lung cancer is still low. It is vital to identify new prognostic markers to develop personalized treatments for patients with lung cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.